Black Diamond Therapeutics (BDTX) Net Cash Flow: 2018-2024
Historic Net Cash Flow for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to -$19.8 million.
- Black Diamond Therapeutics' Net Cash Flow rose 188.90% to $19.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $31.2 million, marking a year-over-year increase of 126.24%. This contributed to the annual value of -$19.8 million for FY2024, which is 191.78% down from last year.
- Per Black Diamond Therapeutics' latest filing, its Net Cash Flow stood at -$19.8 million for FY2024, which was down 191.78% from $21.6 million recorded in FY2023.
- Over the past 5 years, Black Diamond Therapeutics' Net Cash Flow peaked at $31.2 million during FY2021, and registered a low of -$118.9 million during FY2020.
- For the 3-year period, Black Diamond Therapeutics' Net Cash Flow averaged around -$9.9 million, with its median value being -$19.8 million (2024).
- As far as peak fluctuations go, Black Diamond Therapeutics' Net Cash Flow plummeted by 215.36% in 2020, and later spiked by 168.36% in 2023.
- Black Diamond Therapeutics' Net Cash Flow (Yearly) stood at -$118.9 million in 2020, then spiked by 126.24% to $31.2 million in 2021, then plummeted by 201.11% to -$31.5 million in 2022, then surged by 168.36% to $21.6 million in 2023, then slumped by 191.78% to -$19.8 million in 2024.